Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report by Technology (NGS, PCR), Cancer Type (Hemopathy), By End Use (Hospitals), By Region and Forecast segments, 2023-2030
New York, Jan. 06, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Analysis Report of Minimal Residual Disease Testing Market Size, Share and Trends by Technology, Cancer Type , by End Use, by Region and Industry Forecast, 2023 – 2030” – https://www.reportlinker.com/p06377983/?utm_source=GNW
Minimal Residue Disease Testing Market Growth and Trends
The global minimal residual disease testing market size is expected to reach USD 4.50 billion by 2030, growing at a CAGR of 11.45% from 2023 to 2030. The adoption of MRD testing as a new diagnostic test and prognosis facilitates robust moderation of treatment regimens to treat all types of hematological malignancies. The measurement of treatment outcomes is essential for the successful adoption of a given cancer treatment regimen.
MRD generates important molecular information to better understand cancer conditions and ultimately to leverage treatment outcomes. results due to individual genetic characteristics.
For example, in November 2020, Adaptive Biotechnologies Corporation, entered into a collaboration with GlaxoSmithKline plc., to use its clonoSEQ assay for the evaluation of residual cancer cells after treatment with GSK hematology therapeutics.
Surgical removal of tumors with other combination therapies does not essentially mean that cancer cells are completely eliminated. Traces of cancer may remain in body parts and in the bloodstream.
The diagnosis of these residual cells is crucial to decide on the need for new rounds of chemotherapy and radiotherapy. Researchers are designing non-invasive tests to effectively detect MRD.
For example, in February 2022, a blood test by C2i Genomics quantified residual cancer cells after oncology surgeries. The C2inform test has also obtained CE Mark clearance and is offered as a “software as a medical device” MRD test in Europe.
Cancer therapies are effectively moderated to avoid residual tumor cells using relevant clinical evidence and are also personalized based on specific progression profiles in an individual. Numerous research studies lead to the need to take into account individual genetic characteristics for effective treatment.
For example, in October 2022, Adaptive Biotechnologies Corporation partnered with Epic to increase access to MRD monitoring in blood cancers. Additionally, in February 2021, Natera Inc., collaborated with Personalis Inc., to understand personalized cancer care outcomes by integrating NeXT tumor profiling (by Personalis) and personalized diagnostic products from the ctDNA Signatera platform ( by Natera, Inc.,) to effectively design the treatment monitoring regimen and evaluation of MRD.
Highlights of the Minimal Residue Disease Testing Market Report
• Flow cytometry segment held dominant share in minimal residual disease testing market in 2022 due to high sensitivity and wide applicability of MRD testing
• Hematological malignancies segment is expected to grow at the fastest rate over the forecast period owing to the rising prevalence of hematological malignancies
• Hospitals and specialty clinics segment is the most revenue-generating segment in 2022 due to the availability of advanced diagnostic devices and skilled professionals in hospitals and specialty clinics
• North America led the minimal residual disease testing market in 2022, which is attributed to the growing prevalence of hematological malignancies in the region, aided by a well-developed reimbursement landscape
Read the full report: https://www.reportlinker.com/p06377983/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001